Drug Approval | April 10, 2023
Virpax reports on progress of Envelta
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Integration of modern and traditional medicine to facilitate the illness to wellness journey
This is especially the case if the patients are young, have multiple blocks & have conditions that may make angioplasty to implant drug-eluting stents ineffective
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
Time to combine innovation, access and technology to deliver positive patient outcomes
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Subscribe To Our Newsletter & Stay Updated
